

Award Number: W81XWH-06-1-0454

TITLE: The Role of ABC Proteins in Drug Resistant Breast Cancer Cells

PRINCIPAL INVESTIGATOR: Perri Pleeter  
Jacqueline K. Lekostaj

CONTRACTING ORGANIZATION: Georgetown University  
Washington, DC 20057

REPORT DATE: March 2009

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

<b>1. REPORT DATE</b> 1 March 2009		<b>2. REPORT TYPE</b> Annual Summary		<b>3. DATES COVERED</b> 14 Mar 2008 – 13 Mar 2009	
<b>4. TITLE AND SUBTITLE</b>  The Role of ABC Proteins in Drug Resistant Breast Cancer Cells				<b>5a. CONTRACT NUMBER</b>	
				<b>5b. GRANT NUMBER</b> W81XWH-06-1-0454	
				<b>5c. PROGRAM ELEMENT NUMBER</b>	
<b>6. AUTHOR(S)</b>  Perri Pleeter, Jacqueline K. Lekostaj  E-Mail: jkl25@georgetown.edu; PGP8@Georgetownuniversity.edu				<b>5d. PROJECT NUMBER</b>	
				<b>5e. TASK NUMBER</b>	
				<b>5f. WORK UNIT NUMBER</b>	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b>  Georgetown University Washington, DC 20057				<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>	
				<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>	
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited					
<b>13. SUPPLEMENTARY NOTES</b>					
<b>14. ABSTRACT</b> This predoctoral training grant, supported by the Department of Defense Breast Cancer Research Program (BCRP) of the Office of the Congressionally Directed Medical Research Programs (CDMRP), aims to study the possible role of membrane transporters in pleiotropic drug resistance, using a combination of molecular biological, biochemical, and biophysical methods. The third year of funding was spent in further characterization of the Plasmodium falciparum Chloroquine Transporter (PfCRT), a member of a drug/metabolite transporter superfamily. Data from the previous year provided proof of the protein's direct interaction with its drug substrate. I have subsequently employed a methodology commonly applied to drug resistance proteins (such as human P-glycoprotein) and defined the drug binding site through mass spectrometry. This report summarizes work conducted from March 2008 through June 2008, when my work on this project ceased due to graduation. A request for a change of PI for this award has been submitted and is pending review.					
<b>15. SUBJECT TERMS</b> Drug resistance, drug transporters, photoaffinity labeling, mass spectrometry					
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>	<b>18. NUMBER OF PAGES</b>	<b>19a. NAME OF RESPONSIBLE PERSON</b>
<b>a. REPORT</b>	<b>b. ABSTRACT</b>	<b>c. THIS PAGE</b>			<b>USAMRMC</b>
U	U	U	UU	10	<b>19b. TELEPHONE NUMBER (include area code)</b>

Table of Contents

	<u>Page</u>
<b>Introduction .....</b>	<b>4</b>
<b>Body .....</b>	<b>4</b>
<b>Key Research Accomplishments .....</b>	<b>9</b>
<b>Reportable Outcomes .....</b>	<b>9</b>
<b>Conclusion .....</b>	<b>10</b>
<b>References .....</b>	<b>10</b>
<b>Appendices .....</b>	<b>10</b>


## INTRODUCTION

Human P-glycoprotein (Pgp) is a transmembrane glycoprotein implicated in contributing to the resistance of cancer cell lines to chemotherapeutic drugs. The most popular model for the action of Pgp is active drug efflux. Pgp is thought to bind to polar drugs that have passively diffused through the lipid bilayer of the membrane into the cell and actively pump them out, even against a concentration gradient [1]. An alternative hypothesis accounting for the decreased accumulation of drugs in multidrug resistant (MDR) cells is that the altered partitioning of the drugs between the extracellular and intracellular compartments is due to a perturbation in the chemical environment and/or the number of drug binding sites [2]. Regardless of the mechanism of action, it is now generally accepted that Pgp alone cannot fully account for the spectrum of drug resistance found clinically [3]. This predoctoral training grant, supported by the Department of Defense Breast Cancer Research Program (BCRP) of the Office of the Congressionally Directed Medical Research Programs (CDMRP), aims to study the possible role of membrane drug transporters in pleiotropic drug resistance, using a combination of molecular biological, biochemical, and biophysical methods.


## BODY


In my first year of work on this project, I heterologously expressed and characterized the P-glycoprotein homologue, the *Plasmodium falciparum* Multidrug Resistance protein (PfMDR1). I found very little remarkable drug stimulation or inhibition of ATPase activity. The contribution of PfMDR1 to malarial drug resistance seems minimal, at best playing a modulatory role in the resistance pre-determined by other factors. In the second year of work, I focused on the photoaffinity labeling of the *Plasmodium falciparum* Chloroquine Resistance Transporter (PfCRT) with a novel perfluoro-azido-biotinylated chloroquine (CQ) analog called AzBCQ. My results showed that CQ does in fact directly interact with the protein, and competition studies also suggested a physical interaction with other quinoline drugs (*e.g.* quinine), as well as the chemoreversal agent verapamil.

During my abbreviated third year of work, I further characterized the CQ -PfCRT interaction by defining the drug binding site, as has previously been done for human Pgp [4 -7]. As a first step, PfCRT (which is labeled with a polyHis tag) was reacted with AzBCQ and then partially digested with trypsin (Figure 1). The major initial degradation product was ~17 kDa and must be the C-terminus of the protein as it retains the polyHis tag (Figure 2). Further digestion did not allow for resolution of smaller labeled fragments, although a ~6.5 kDa unlabeled and non anti-his reactive fragment was identified on anion silver-stained gels.










**Figure 1** Avidin blot of trypsin digest of AzBCQ -labeled PfCRT. Lane 1, MW standards; lane 2, trypsin enzyme alone; lane 3, undigested PfCRT; lanes 4 -9, PfCRT digested with trypsin for 2.5, 5, 10, 15, 20, and 30 min respectively.





**Figure 2** Identification of the major tryptic fragment as the C-terminus. (A) silver stain, (B) avidin blot, and (C) polyHis blot of tryptic digest of AzBCQ-labeled PfCRT. Lane 1, MW standards; lane 2, trypsin; lane 3, undigested PfCRT; lane 4, PfCRT digested with trypsin for 2.5 min.

The labeled protein fragment was excised from the silver stained gel (Figure 2A) and sent for mass spectrometry analysis. The peaks from the resulting mass spectrum (Figure 3) were examined for their amino acid composition. A few peaks corresponded to keratin (a ubiquitous contaminant from human skin) and one to a trypsin autolytic fragment. Peptides corresponding to PfCRT amino acids 285 -317 and 405 -424 were also identified. Additionally, one low -mass peak could represent either a tripeptide from keratin or PfCRT amino acids 372-374. Since their masses corresponded exactly to the observed MS peaks  $\pm 0.5$  Da, these fragments cannot contain the AzBCQ tag.



mass (Da)	amino acid position	peptide sequence
1768.9380	271-284	QLHLPYNEIWTNIK
1097.5560	285-294	NGFACLFLGR
1335.6395	295-307	NTVVENCGLGMAK
1125.4339	308-317	LCDDCDGAWK
2585.2996	318-339	TFALFSFFNICDNLITSYII DK
2688.3452	340-363	FSTMTYTIVSCIQGPAAIAIAYYFK
876.4937	364-371	FLAGDVVR
401.2143	372-374	EPR
2137.1732	375-392	LLDFVTLFGYLFSGSIYR
913.5465	393-400	VGNIILER
147.1128	401-401	K
147.1128	402-402	K
306.1594	403-404	MR
2235.9735	405-424	NEENEDSEGELTNVDSIITQ

**Table 1** Predicted tryptic fragments of the C-terminal 17 kDa of PfCRT.


Upon UV activation, the AzBCQ molecule loses  $N_2$ , resulting in an adduct with MW 766.25 Da. Subtraction of this value from the masses of all peaks displayed in the peptide m/z spectrum yielded only one peak that corresponds to a predicted tryptic fragment residing with the C-terminal region of PfCRT. That peak has m/z of 2024.64, which is within 0.30 Da of that expected for the peptide defined by residues 364 – 374 (Figure 4, bold). The AzBCQ must therefore be attached to one of these amino acids. Moreover, the last three amino acids of this segment are those that may correspond to the low-mass unlabeled fragment mentioned earlier, thereby further narrowing the possible positions for the label. These residues are believed to comprise the intra-digestive vacuolar loop connecting putative helices 9 and 10 (Figure 4, underlined) of PfCRT protein, and contained within this sequence is position 371, which is known to be mutated in some CQ-resistant strains.

...QLHLPYNEIWTNIK**NGFACLFLGR**NTVVENCGLGMAK  
 LCDDCDGAW**K**TFALFSFFNICDNLITSYIID**K**FSTMTY  
 TIVSCIQGPAAIAIAYY**F****FLAGDVVREP**LLDFVTLFG  
 YLFGSIIY**RV**GNII**L**ER**KK**MR**NEENEDSEGELTNVDSI**  
**ITQ**

**Figure 4** C-terminal sequence of PfCRT containing the AzBCQ binding site. Shown are amino acids 284-324, corresponding to the last 18.6 kDa of the protein. Unlabeled peptide fragments identified by MS are in *italics*, predicted transmembrane domains are underlined, and the AzBCQ-bound fragment is in **bold**.

Finally, I collaborated with a protein modeler to elucidate the nature of the CQ-PfCRT interaction in 3-dimensional space. Previous work with drug-selected parasite lines [8] suggested that helices 1 and 9 are important to the protein's drug-interaction capabilities, and energy-minimized models are consistent with this hypothesis (Figure 5).





**Figure 5** *Ribbon diagram of proposed PfCRT drug binding pocket.* The CQ pharmacophore is predicted to lie within the lower third of the membrane, while the bulky biotin and perfluorophenyl azido groups stretch into the parasite digestive vacuole, with the latter making contact with (and inserting into) the interhelix loop of amino acids. Asterisks mark sections of helices that contain mutations associated with CQ resistance.

## KEY ACCOMPLISHMENTS

### Research Accomplishments

- Definition of the PfCRT CQ-binding site

### Training Accomplishments

- Successful defense of dissertation, June 30 2008
- Graduation with Doctorate in Tumor Biology

## REPORTABLE OUTCOMES

- Published Thesis: Lekostaj, JK. (2008) Molecular Analysis of Membrane Transporters Implicated in Drug Resistance.
- Published Article: Lekostaj JK, Natarajan JK, Paguio MF, Wolf C, Roep e PD. (2008) Photoaffinity labeling of the *Plasmodium falciparum* chloroquine resistance transporter with a novel perfluorophenylazido chloroquine. *Biochemistry*. 47(39): 10394-406.

## CONCLUSION

In the three months of this year supported by this research grant, I utilized photoaffinity labeling combined with enzymatic digestion and mass spectrometry to define the drug binding site of PfCRT, a member of a drug/metabolite transporter superfamily that is thought to be vitally important in malarial multidrug resistance. My data supports a direct physical interaction between the protein and the drug, which allows for the possibility of active drug efflux, or pumping. Furthermore, the identified drug binding pocket is conceptually consistent with data from other investigators that together offer potential explanations for the differences between wildtype and mutant proteins.

A request for a change of PI for this award has been submitted and is pending review of this summary.

## REFERENCES

- [1] Riordan JR and Ling V. (1985) Genetic and biochemical characterization of multidrug resistance. *Pharmacol Ther.* 28(1): 51-75.
- [2] Hoffman MM, Wei LY and Roepe PD. (1996) Are altered pH<sub>i</sub> and membrane potential in hu MDR 1 transfectants sufficient to cause MDR protein -mediated multidrug resistance? *J Gen Physiol.* 108(4): 295-313.
- [3] McDevitt CA and Callaghan R. (2007) How can we best use structural information on P - glycoprotein to design inhibitors? *Pharmacol Ther.* 113(2): 429-41.
- [4] Safa AR, Glover CJ, Meyers MB, Biedler JL and Felsted RL. (1986) Vinblastine photoaffinity labeling of a high molecular weight surface membrane glycoprotein specific for multidrug-resistant cells. *J Biol Chem.* 261(14):6137-40.
- [5] Bruggemann EP, Germann UA, Gottesman MM and Pastan I. (1989) Two different regions of P-glycoprotein are photoaffinity -labeled by azidopine. *J Biol Chem.* 264(26): 15483-8. Erratum in: *J Biol Chem* (1990), 265(7): 4172.
- [6] Bruggemann EP, Currier SJ, Gottesman MM and Pastan I. (1992) Characterization of the azidopine and vinblastine binding site of P-glycoprotein. *J Biol Chem.* 267(29): 21020-6.
- [7] Morris DI, Greenberger LM, Bruggemann EP, Cardarelli C, Gottesman MM, Pastan I and Seamon KB. (1994) Localization of the forskolin labeling sites to both halves of P-glycoprotein: similarity of the sites labeled by forskolin and prazosin. *Mol Pharmacol.* 46(2): 329-37.
- [8] Cooper RA, Lane KD, Deng B, Mu J, Patel JJ, Wellems TE, Su X and Ferdig MT. (2007) Mutations in transmembrane domains 1, 4 and 9 of the *Plasmodium falciparum* chloroquine resistance transporter alter susceptibility to chloroquine, quinine and quinidine. *Mol Microbiol.* 63(1): 270-82.

## APPENDICES

none